Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLFQKU)

• Drug Name: pyrazolone, 1 Drug Info
• Synonyms: compound 43 [PMID:23160941]; compound 43 [PMID:16697190]

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 24776341
  CAS Number: CAS 903895-98-7
  TTD Drug ID: DMLFQKU

Molecule-Related Drug Atlas

Drug(s) Targeting N-formyl peptide receptor (FPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rebamipide	DM2GHCR	Peptic ulcer	DA61	Phase 3	[3]
PMID22607879CR-(-)-5f	DM7OJ5Q	Discovery agent	N.A.	Investigative	[4]
fMet-Leu-Phe	DMQ391A	N. A.	N. A.	Investigative	[5]
group E 1682-2106	DMO6IM1	Discovery agent	N.A.	Investigative	[6]
BVT173187	DMULZOP	Discovery agent	N.A.	Investigative	[7]
CGEN-855	DM4FMPJ	Inflammation	1A00-CA43.1	Investigative	[8]
AG-11/03	DMZINUY	Discovery agent	N.A.	Investigative	[9]
methionine benzimidazole 6	DMEIP6H	Discovery agent	N.A.	Investigative	[10]
AG-09/1	DMW7H28	Discovery agent	N.A.	Investigative	[11]
diamide 7	DM4EX8Y	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting FMLP-related receptor I (FPR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
humanin	DMUAPNF	Alzheimer disease	8A20	Preclinical	[12]
[3H]resolvin D1	DMFT0HU	Discovery agent	N.A.	Investigative	[13]
LXA4	DMGSVL0	Discovery agent	N.A.	Investigative	[13]
PMID22607879CR-(-)-5f	DM7OJ5Q	Discovery agent	N.A.	Investigative	[4]
aspirin-triggered resolvin D1	DMOP941	Discovery agent	N.A.	Investigative	[14]
fMet-Leu-Phe	DMQ391A	N. A.	N. A.	Investigative	[15]
RvD1-ME	DM8EZTM	Discovery agent	N.A.	Investigative	[14]
quin-C7	DM1CYWB	Discovery agent	N.A.	Investigative	[16]
aspirin triggered lipoxin A4	DMLBSNP	Discovery agent	N.A.	Investigative	[17]
quin-C1	DMVQYWS	Discovery agent	N.A.	Investigative	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
FMLP-related receptor I (FPR2)	TTOJ1NF	FPR2_HUMAN	Agonist	[2]
N-formyl peptide receptor (FPR1)	TT5Y4EM	FPR1_HUMAN	Agonist	[1]

References

• [1] Functional characterization of three mouse formyl peptide receptors. Mol Pharmacol. 2013 Feb;83(2):389-98.
• [2] Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3713-8.
• [3] Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94.
• [4] Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92.
• [5] Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry. 1980 May 27;19(11):2404-10.
• [6] Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol. 2005 Nov;68(5):1301-10.
• [7] A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. Biochem Pharmacol. 2012 Jun 15;83(12):1655-62.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 222).
• [9] Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1. J Mol Model. 2012 Jun;18(6):2831-43.
• [10] Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett. 2011 May 15;21(10):2991-7.
• [11] Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol. 2010 Feb;77(2):159-70.
• [12] N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004 Nov 5;324(1):255-61.
• [13] Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5.
• [14] Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27.
• [15] Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem. 1993 Aug 25;268(24):18167-75.
• [16] Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007 Oct;72(4):976-83.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 223).
• [18] A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004 Nov;66(5):1213-22.